Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Upfront licensing & in-process R&D milestone payments by Year
Upfront licensing & in-process R&D (IPR&D) milestone payments ($M) ($M)
Moderna Upfront licensing & in-process R&D milestone payments: $88M in FY2025, down 43.2% from a year earlier.
Latest, FY2025
88
Period ended Dec 31, 2025
Change on a year earlier
-43.2%
155 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Cash Flows.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Upfront licensing & in-process R&D (IPR&D) milestone payments ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 88 | -43.2% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 155 | -48.5% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 301 | -72.6% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 1,100 | +71.6% | Form 10-K (filed 2025-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 641 | +9,057.1% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 7 | – | Form 10-K (filed 2023-02-24) ↗ |
Cite this data
StockData. (2026). Moderna Upfront licensing & in-process R&D milestone payments ($M), annual FY2020–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/iprd-paid
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.